Chapters

Transcript

Colon cancer study

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

"For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them," says Dr. Grothey. "This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options."


Published

February 27, 2014

Created by

Mayo Clinic